Psychemedics Corporation (PMD)
USD 2.67
(0.0%)
USD 2.67
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 334 Thousand USD | 128.4% |
| 2022 | -1.17 Million USD | -137.51% |
| 2021 | 3.13 Million USD | -48.34% |
| 2020 | 6.06 Million USD | 561.17% |
| 2019 | -1.31 Million USD | 46.09% |
| 2018 | -2.44 Million USD | 49.02% |
| 2017 | -4.78 Million USD | -759.61% |
| 2016 | -557 Thousand USD | -117.39% |
| 2015 | 3.2 Million USD | 21.49% |
| 2014 | 2.63 Million USD | 166.39% |
| 2013 | -3.97 Million USD | -29.51% |
| 2012 | -3.06 Million USD | 44.9% |
| 2011 | -5.56 Million USD | -49.56% |
| 2010 | -3.72 Million USD | 23.14% |
| 2009 | -4.84 Million USD | 26.99% |
| 2008 | -6.63 Million USD | -8.75% |
| 2007 | -6.09 Million USD | -45.85% |
| 2006 | -4.18 Million USD | -24.69% |
| 2005 | -3.35 Million USD | -2.83% |
| 2004 | -3.26 Million USD | -7.86% |
| 2003 | -3.02 Million USD | 17.17% |
| 2002 | -3.64 Million USD | -17.3% |
| 2001 | -3.11 Million USD | 9.43% |
| 2000 | -3.43 Million USD | -390.66% |
| 1999 | -700 Thousand USD | 0.0% |
| 1998 | -700 Thousand USD | -16.67% |
| 1997 | -600 Thousand USD | 60.0% |
| 1996 | -1.5 Million USD | -733.33% |
| 1995 | -180 Thousand USD | 40.0% |
| 1994 | -300 Thousand USD | 57.14% |
| 1993 | -700 Thousand USD | 30.0% |
| 1992 | -1 Million USD | 41.18% |
| 1991 | -1.7 Million USD | -440.0% |
| 1990 | 500 Thousand USD | 600.0% |
| 1989 | -100 Thousand USD | 75.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 434 Thousand USD | -19.48% |
| 2024 Q1 | 539 Thousand USD | 61.38% |
| 2023 Q1 | -1.05 Million USD | 10.2% |
| 2023 FY | 334 Thousand USD | 128.4% |
| 2023 Q4 | 334 Thousand USD | -73.76% |
| 2023 Q3 | 1.27 Million USD | 135.3% |
| 2023 Q2 | 541 Thousand USD | 151.23% |
| 2022 Q4 | -1.17 Million USD | -351.82% |
| 2022 Q2 | 2.55 Million USD | -2.22% |
| 2022 Q1 | 2.61 Million USD | -16.65% |
| 2022 FY | -1.17 Million USD | -137.51% |
| 2022 Q3 | 467 Thousand USD | -81.72% |
| 2021 Q4 | 3.13 Million USD | -14.74% |
| 2021 Q2 | 5.59 Million USD | -13.83% |
| 2021 FY | 3.13 Million USD | -48.34% |
| 2021 Q1 | 6.49 Million USD | 6.95% |
| 2021 Q3 | 3.67 Million USD | -34.26% |
| 2020 Q1 | 229 Thousand USD | 117.4% |
| 2020 Q4 | 6.06 Million USD | -18.6% |
| 2020 FY | 6.06 Million USD | 561.17% |
| 2020 Q2 | 5.99 Million USD | 2517.47% |
| 2020 Q3 | 7.45 Million USD | 24.39% |
| 2019 Q3 | -1.64 Million USD | 61.41% |
| 2019 Q1 | -102 Thousand USD | 95.82% |
| 2019 FY | -1.31 Million USD | 46.09% |
| 2019 Q4 | -1.31 Million USD | 19.95% |
| 2019 Q2 | -4.26 Million USD | -4076.47% |
| 2018 Q2 | -4.82 Million USD | 6.3% |
| 2018 Q1 | -5.14 Million USD | -7.48% |
| 2018 FY | -2.44 Million USD | 49.02% |
| 2018 Q3 | -3.35 Million USD | 30.4% |
| 2018 Q4 | -2.44 Million USD | 27.26% |
| 2017 Q1 | -3.77 Million USD | -577.56% |
| 2017 Q3 | -4.13 Million USD | -204.87% |
| 2017 Q4 | -4.78 Million USD | -15.82% |
| 2017 FY | -4.78 Million USD | -759.61% |
| 2017 Q2 | -1.35 Million USD | 64.07% |
| 2016 Q4 | -557 Thousand USD | -150.0% |
| 2016 Q1 | 4.09 Million USD | 27.81% |
| 2016 Q3 | 1.11 Million USD | -67.05% |
| 2016 FY | -557 Thousand USD | -117.39% |
| 2016 Q2 | 3.38 Million USD | -17.39% |
| 2015 FY | 3.2 Million USD | 21.49% |
| 2015 Q3 | 4.57 Million USD | 32.83% |
| 2015 Q4 | 3.2 Million USD | -30.0% |
| 2015 Q2 | 3.44 Million USD | 9.25% |
| 2015 Q1 | 3.15 Million USD | 19.6% |
| 2014 Q1 | -1.15 Million USD | 70.89% |
| 2014 Q4 | 2.63 Million USD | -33.88% |
| 2014 Q3 | 3.98 Million USD | 10.77% |
| 2014 Q2 | 3.59 Million USD | 411.36% |
| 2014 FY | 2.63 Million USD | 166.39% |
| 2013 Q1 | -2.51 Million USD | 18.04% |
| 2013 Q3 | -2.84 Million USD | -4.16% |
| 2013 Q4 | -3.97 Million USD | -39.67% |
| 2013 FY | -3.97 Million USD | -29.51% |
| 2013 Q2 | -2.72 Million USD | -8.62% |
| 2012 FY | -3.06 Million USD | 44.9% |
| 2012 Q1 | -4.72 Million USD | 15.07% |
| 2012 Q4 | -3.06 Million USD | 16.32% |
| 2012 Q2 | -4.76 Million USD | -0.76% |
| 2012 Q3 | -3.66 Million USD | 23.07% |
| 2011 Q2 | -2.61 Million USD | 3.71% |
| 2011 Q1 | -2.71 Million USD | 26.91% |
| 2011 FY | -5.56 Million USD | -49.56% |
| 2011 Q3 | -3.5 Million USD | -33.73% |
| 2011 Q4 | -5.56 Million USD | -58.91% |
| 2010 FY | -3.72 Million USD | 23.14% |
| 2010 Q3 | -2.87 Million USD | -7.43% |
| 2010 Q4 | -3.72 Million USD | -29.5% |
| 2010 Q2 | -2.67 Million USD | 16.07% |
| 2010 Q1 | -3.18 Million USD | 34.17% |
| 2009 Q2 | -4.95 Million USD | 9.71% |
| 2009 Q4 | -4.84 Million USD | -33.85% |
| 2009 Q1 | -5.48 Million USD | 17.24% |
| 2009 FY | -4.84 Million USD | 26.99% |
| 2009 Q3 | -3.61 Million USD | 27.0% |
| 2008 FY | -6.63 Million USD | -8.75% |
| 2008 Q4 | -6.63 Million USD | 4.06% |
| 2008 Q2 | -7.11 Million USD | -12.81% |
| 2008 Q1 | -6.31 Million USD | -3.5% |
| 2008 Q3 | -6.91 Million USD | 2.91% |
| 2007 Q3 | -4.61 Million USD | -8.99% |
| 2007 Q2 | -4.23 Million USD | -11.72% |
| 2007 Q1 | -3.78 Million USD | 9.38% |
| 2007 FY | -6.09 Million USD | -45.85% |
| 2007 Q4 | -6.09 Million USD | -32.18% |
| 2006 Q2 | -1.99 Million USD | 11.74% |
| 2006 FY | -4.18 Million USD | -24.69% |
| 2006 Q4 | -4.18 Million USD | -37.58% |
| 2006 Q3 | -3.03 Million USD | -52.68% |
| 2006 Q1 | -2.25 Million USD | 32.74% |
| 2005 FY | -3.35 Million USD | -2.83% |
| 2005 Q2 | -2.43 Million USD | -17.61% |
| 2005 Q1 | -2.06 Million USD | 36.54% |
| 2005 Q4 | -3.35 Million USD | -4.71% |
| 2005 Q3 | -3.2 Million USD | -31.59% |
| 2004 Q3 | -3.67 Million USD | -55.12% |
| 2004 Q2 | -2.36 Million USD | 6.99% |
| 2004 Q1 | -2.54 Million USD | 15.7% |
| 2004 FY | -3.26 Million USD | -7.86% |
| 2004 Q4 | -3.26 Million USD | 11.32% |
| 2003 FY | -3.02 Million USD | 17.17% |
| 2003 Q2 | -3.24 Million USD | -2.7% |
| 2003 Q3 | -3.08 Million USD | 5.14% |
| 2003 Q4 | -3.02 Million USD | 1.94% |
| 2003 Q1 | -3.16 Million USD | 13.3% |
| 2002 FY | -3.64 Million USD | -17.3% |
| 2002 Q1 | -2.73 Million USD | 12.07% |
| 2002 Q2 | -3.29 Million USD | -20.33% |
| 2002 Q3 | -3.35 Million USD | -1.81% |
| 2002 Q4 | -3.64 Million USD | -8.89% |
| 2001 Q1 | -2.34 Million USD | 31.7% |
| 2001 Q2 | -2.8 Million USD | -19.76% |
| 2001 Q3 | -2.7 Million USD | 3.78% |
| 2001 FY | -3.11 Million USD | 9.43% |
| 2001 Q4 | -3.11 Million USD | -15.07% |
| 2000 FY | -3.43 Million USD | -390.66% |
| 2000 Q4 | -3.43 Million USD | -2.56% |
| 2000 Q3 | -3.34 Million USD | -220.73% |
| 2000 Q1 | -1.2 Million USD | -71.5% |
| 2000 Q2 | -1.04 Million USD | 13.03% |
| 1999 FY | -700 Thousand USD | 0.0% |
| 1999 Q1 | -500 Thousand USD | 28.57% |
| 1999 Q2 | -900 Thousand USD | -80.0% |
| 1999 Q4 | -700 Thousand USD | -40.0% |
| 1999 Q3 | -500 Thousand USD | 44.44% |
| 1998 Q1 | -1.7 Million USD | -183.33% |
| 1998 FY | -700 Thousand USD | -16.67% |
| 1998 Q4 | -700 Thousand USD | -133.33% |
| 1998 Q3 | -300 Thousand USD | -900.0% |
| 1998 Q2 | -30 Thousand USD | 98.24% |
| 1997 Q2 | -700 Thousand USD | -16.67% |
| 1997 Q3 | -400 Thousand USD | 42.86% |
| 1997 FY | -600 Thousand USD | 60.0% |
| 1997 Q1 | -600 Thousand USD | 60.0% |
| 1997 Q4 | -600 Thousand USD | -50.0% |
| 1996 Q1 | -2.7 Million USD | -1400.0% |
| 1996 Q2 | -1.3 Million USD | 51.85% |
| 1996 FY | -1.5 Million USD | -733.33% |
| 1996 Q4 | -1.5 Million USD | -114.29% |
| 1996 Q3 | -700 Thousand USD | 46.15% |
| 1995 Q2 | -600 Thousand USD | -100.0% |
| 1995 FY | -180 Thousand USD | 40.0% |
| 1995 Q3 | -300 Thousand USD | 50.0% |
| 1995 Q4 | -180 Thousand USD | 40.0% |
| 1995 Q1 | -300 Thousand USD | 0.0% |
| 1994 Q3 | -5.8 Million USD | -16.0% |
| 1994 Q1 | -1.5 Million USD | -114.29% |
| 1994 FY | -300 Thousand USD | 57.14% |
| 1994 Q2 | -5 Million USD | -233.33% |
| 1994 Q4 | -300 Thousand USD | 94.83% |
| 1993 Q1 | -400 Thousand USD | 60.0% |
| 1993 Q2 | -500 Thousand USD | -25.0% |
| 1993 Q3 | -600 Thousand USD | -20.0% |
| 1993 Q4 | -700 Thousand USD | -16.67% |
| 1993 FY | -700 Thousand USD | 30.0% |
| 1992 FY | -1 Million USD | 41.18% |
| 1992 Q1 | -1.7 Million USD | 0.0% |
| 1992 Q4 | -1 Million USD | 0.0% |
| 1991 Q4 | -1.7 Million USD | 0.0% |
| 1991 Q1 | -300 Thousand USD | -160.0% |
| 1991 FY | -1.7 Million USD | -440.0% |
| 1990 Q4 | 500 Thousand USD | 0.0% |
| 1990 FY | 500 Thousand USD | 600.0% |
| 1989 Q2 | -1.3 Million USD | 0.0% |
| 1989 FY | -100 Thousand USD | 75.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -39.45 Million USD | 100.847% |
| Applied DNA Sciences, Inc. | -5.91 Million USD | 105.648% |
| Aspira Women's Health Inc. | -331 Thousand USD | 200.906% |
| Biodesix, Inc. | 34.3 Million USD | 99.026% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | 105.763% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 126.872% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 126.872% |
| Bionano Genomics, Inc. | 34.88 Million USD | 99.042% |
| CareDx, Inc | -47.97 Million USD | 100.696% |
| Check-Cap Ltd. | -24.75 Million USD | 101.349% |
| Castle Biosciences, Inc. | -83.53 Million USD | 100.4% |
| DarioHealth Corp. | -7.54 Million USD | 104.425% |
| Exact Sciences Corporation | 1.94 Billion USD | 99.983% |
| Fulgent Genetics, Inc. | -82.56 Million USD | 100.405% |
| Guardant Health, Inc. | 220.22 Million USD | 99.848% |
| ICON Public Limited Company | 3.56 Billion USD | 99.991% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | 99.932% |
| Illumina, Inc. | 1.21 Billion USD | 99.972% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | 106.148% |
| iSpecimen Inc. | -2.14 Million USD | 115.554% |
| Standard BioTools Inc. | 46.5 Million USD | 99.282% |
| MDxHealth SA | 18.88 Million USD | 98.231% |
| 23andMe Holding Co. | -141.37 Million USD | 100.236% |
| Medpace Holdings, Inc. | -103.32 Million USD | 100.323% |
| Myriad Genetics, Inc. | 88.1 Million USD | 99.621% |
| Mainz Biomed B.V. | 349.85 Thousand USD | 4.532% |
| ENDRA Life Sciences Inc. | -2.43 Million USD | 113.691% |
| NeoGenomics, Inc. | 269.19 Million USD | 99.876% |
| Neogen Corporation | 735.62 Million USD | 99.955% |
| Inotiv, Inc. | 382.14 Million USD | 99.913% |
| Natera, Inc. | -200.1 Million USD | 100.167% |
| OpGen, Inc. | 11.89 Million USD | 97.191% |
| OPKO Health, Inc. | 230.68 Million USD | 99.855% |
| Prenetics Global Limited | -43.33 Million USD | 100.771% |
| Prenetics Global Limited | -43.33 Million USD | 100.771% |
| Precipio, Inc. | -386 Thousand USD | 186.528% |
| Personalis, Inc. | -8.02 Million USD | 104.164% |
| RadNet, Inc. | 1.14 Billion USD | 99.971% |
| Sera Prognostics, Inc. | -2.02 Million USD | 116.518% |
| Sotera Health Company | 2.02 Billion USD | 99.984% |
| Neuronetics, Inc. | 2.79 Million USD | 88.059% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 102.178% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 102.178% |
| Trinity Biotech plc | 63.73 Million USD | 99.476% |
| T2 Biosystems, Inc. | 33.8 Million USD | 99.012% |
| Twist Bioscience Corporation | -192.4 Million USD | 100.174% |
| Exagen Inc. | -12.77 Million USD | 102.615% |